Nanotechnology Now - Press Release: "Endomagnetics Strengthens its Operations: Makes Two Key Appointments"

Home > Press > Endomagnetics Strengthens its Operations: Makes Two Key Appointments

Abstract:
Endomagnetics, the company developing advanced magnetic sensing technology for use in cancer staging, has announced two key appointments as it expands in its new Cambridge base. Dr Andrew Shawcross has been appointed Director Operations and Dr Quentin Harmer is the new Director Technology. Both appointments are with immediate effect.

Endomagnetics Strengthens its Operations: Makes Two Key Appointments

Cambridge, UK | Posted on November 22nd, 2011

Dr Shawcross brings over twenty years of experience in operational and project management and will help grow the operational capabilities of Endomagnetics and support its manufacturers and supply chain. Dr Shawcross has held senior positions at ICI, Zeneca, Avecia and latterly at Cambridge Display Technology (CDT) where he was Business Development Manager.

Dr Harmer brings more than a decade of experience in medical devices and will help develop Endomagnetics' technical and regulatory capabilities. Dr Harmer joins from Vectura Group plc where he was Project Director on dry powder inhaler products, and was previously responsible for the development of the Aspirair dry powder inhaler technology at Cambridge Consultants.

Both Shawcross and Harmer bring a strong combination of deep technical background with commercial experience in developing and delivering technology to the market. They join Endomagnetics at an important time as the company prepares to launch its SentiMag® system with its magnetic tracer, Sienna+™, on the European market.

"I am delighted to welcome both Andrew and Quentin in these important new roles at Endomagnetics", said Dr Eric Mayes, Chief Executive Officer. "We are entering an exciting phase as we accelerate the market introduction of the technology, and their combined skills significantly expand the capabilities of the management team."

Magnetic sensing for cancer staging has the potential to replace the current standard of care of using radioactive isotopes. Radioisotopes limit the availability of the current best practice SLNB technique to around half of eligible patients in the West, and a much smaller proportion in Asia.

####

About Endomagnetics
Endomagnetics solves cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.

The company’s first product, the SentiMag®, is an ultrasensitive hand-held probe for detecting a magnetic tracer called Sienna+™ to help identify critical lymph nodes in support of cancer staging. Cambridge-based Endomagnetics is in the process of delivering its technology to global markets.

For more information, please click here

Contacts:
Editorial contact:
Terry Nicklin
KeynotePR Ltd
Tel: +44 (0)7923 540695
E-mail:

Company contact:
Dr Eric Mayes
CEO
Endomagnetics Ltd
Tel: +44 (0)1223 437131
E-mail: